CLGNNasdaqOrthopedic, Prosthetic & Surgical Appliances & SuppliesFiscal year ends December 31
CollPlant Biotechnologies Ltd
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 26, 2026
$3.56−0.06 (-1.79%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2015 to 2025
Gross margin
64.8%+13.7 pts over 5 years
Operating margin
-484.3%−393.1 pts over 5 years
Net margin
-484.6%−390.5 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +360.4% | +99.4% | -17.3% | – | |
| Gross profit | – | – | -13.3% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -134.8% | -117.6% | |
| Return on assets | – | -53.5% | -77.9% | |
| Current ratio | – | 1.68 | 2.53 | |
| Interest coverage | – | – | – | |
| Inventory turnover | – | 2.8× | 1.6× | |
| Capex to revenue | – | 7.1% | 1.2% | |
| Diluted shares | 2M | 7M | 12M |
Where the cash went
Fiscal 2021 to 2025, five years combined
CollPlant Biotechnologies generated $42.47M from operations and spent $4.17M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$42.47M
Used
$4.17M
Capital expenditure$4.17M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-484.6%
×Asset turnover0.16×
×Equity multiplier1.51×
=Return on equity, FY2025-117.6%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -484.6% | 0.16× | 1.51× | -117.6% |
| FY2024 | -3225.0% | 0.02× | 1.26× | -79.5% |
| FY2023 | -64.0% | 0.30× | 1.19× | -23.2% |
| FY2022 | -5660.5% | 0.01× | 1.15× | -43.7% |
| FY2021 | 1.5% | 0.50× | 1.25× | 1.0% |
| FY2020 | -94.1% | 0.57× | 2.52× | -134.8% |
| FY2019 | -481.6% | 0.24× | 2.05× | -234.8% |
| FY2018 | -124.6% | 0.60× | 1.59× | -118.0% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$11.49M
- Cash generatingOperating cash flow above zero-$9.42M
- Return on assets improvedROA up on the prior year-48.7% → -61.4%
- Earnings backed by cashOperating cash flow above net income-$9.42M vs -$11.49M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose4.44 → 2.53
- No dilutionShare count did not rise11M → 12M
- Gross margin improvedGross margin up on the prior year-215.53% → 64.78%
- More efficientAsset turnover rose0.02 → 0.13